A Randomized, Sham-Controlled Trial of Repetitive Transcranial Magnetic Stimulation Targeting M1 and S2 in Central Poststroke Pain: A Pilot Trial.

Juhani OjalaJukka VanhanenHanna HarnoPantelis LioumisSelja VaaltoMari A KaunistoJukka PutaalaMarko KangasniemiErika KirveskariJyrki P MäkeläEija Kalso

Published in: Neuromodulation : journal of the International Neuromodulation Society (2021)

S2 is a promising nrTMS target in the treatment of CPSP. The DRD2 T/T genotype might be a biomarker for M1 nrTMS response, but this needs confirmation from a larger study.

Keyphrases

transcranial magnetic stimulation
high frequency
chronic pain
double blind
neuropathic pain
open label
pain management
spinal cord
clinical trial
drug delivery
spinal cord injury
replacement therapy